Biosimilar ranibizumab (BS1) – early experience from Japan (BRIJ study)

Tomoko Ueda‐Consolvo, Masaaki Ishida, Tomoko Nakamura, Shuichiro Yanagisawa, K. Tsuboi, Taku Wakabayashi, Atsushi Hayashi, Ashish Sharma, International Retina Biosimilar Study Group (Inter BIOS Group), Baruch D. Kuppermann, Anat Loewenstein, Francesco Bandello, Carl D. Regillo, Luke Nicholson, Clara Vazquez-Alfageme, Nilesh Kumar, Nikulaa Parachuri, Jay Sheth, Seemantini Ayachit, Chitaranjan Mishra, Debdulal Chakraborty, Alay Banker, Kourous A. Rezaei, Arshad M. Khanani, Peter K. Kaiser, Ramin Tadayoni, Frank G. Holz, Sobha Sivaprasad, David Sarraf, Giuseppe Querques, Şengül Özdek, Kodjikian Laurent, Alper Bilgic, Paolo Lanzetta, Caroline Baumal, Nancy Holekemp, Taiji Sakamoto, Adnan Tufail, Nicolas Yannuzzi, Giulia Corradetti, Assaf Hilely, David Boyer, Aleksandra Rachitskaya, Tunde Peto, Maximilian W. M. Wintergerst, Valentina Sarao, Barbara Parolini, Prithvi Mruthyunjaya, Quan Dong Nguyen, Diana V. DO, Pearse A. Keane, Tarek Hassan, Jayanth Sridhar, David Eichenbaum, Dilraj S. Grewal, Francesc March, Martin Splitzer, Martin S. Zinkernage